Related Experiment Video
Updated: Dec 27, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Dilated cardiomyopathies and non-compaction cardiomyopathy
A Hänselmann1, C Veltmann1, J Bauersachs1
1Dept. of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Insights
Dilated cardiomyopathy (DCM) is a common heart failure cause, characterized by heart dilation and reduced function. Genetic diagnostics are crucial for risk stratification and understanding hereditary mechanisms in DCM patients.
Area of Science:
- Cardiology
- Genetics
- Heart Failure Research
Background:
- Dilated cardiomyopathy (DCM) is the predominant cardiomyopathy and a leading cause of heart failure.
- It involves left or biventricular dilation and impaired systolic function.
- Etiologies are diverse, including myocarditis, toxins, and systemic diseases, with peripartum cardiomyopathy as a distinct subtype.
Purpose of the Study:
- To highlight the increasing role of genetic diagnostics in identifying DCM causes.
- To emphasize the importance of genetic variants in risk stratification, particularly for arrhythmias.
- To underscore the link between genetic factors and patient prognosis in DCM.
Main Methods:
- Review of current understanding of DCM etiologies.
- Analysis of the impact of genetic diagnostics on DCM patient management.
- Integration of genetic findings with clinical risk stratification for arrhythmias and heart failure.
Main Results:
- Genetic mutations are identified in 30-50% of DCM patients.
- Advances in genetic diagnostics reveal more triggering variants and hereditary mechanisms.
- Genetic variants significantly influence the risk of arrhythmias, impacting patient prognosis.
Conclusions:
- Genetic diagnostics are pivotal in understanding and managing DCM.
- Identifying genetic variants aids in risk stratification for arrhythmias and heart failure.
- Personalized treatment strategies incorporating genetic information are essential for improving DCM patient outcomes.
Abstract:
Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy and one of the most common causes of heart failure. It is characterized by left or biventricular dilation and a reduced systolic function. The causes are manifold and range from myocarditis to alcohol and other toxins, to rheumatological, endocrinological, and metabolic diseases. Peripartum cardiomyopathy is a special form that occurs at the end of or shortly after pregnancy. Genetic mutations can be detected in approximately 30-50% of DCM patients. Owing to the growing possibilities of genetic diagnostics, increasingly more triggering variants and hereditary mechanisms emerge. This is particularly important with regard to risk stratification for patients with variants with an increased risk of arrhythmias. Patient prognosis is determined by the occurrence of heart failure and arrhythmias. In addition to the treatment of the underlying disease or the elimination of triggering harmful toxins, therapy consists in guideline-directed heart failure treatment including drug and device therapy.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Cardiomyopathy V: Interprofessional Care

